Gerdes Sascha, Velasco Manuel, Wu Jashin J, Hubo Mario, Veverka Karen A
Psoriasis Center, Department of Dermatology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Germany.
Hospital Arnau de Vilanova, Valencia, Spain.
J Dermatolog Treat. 2021 Dec;32(8):883-893. doi: 10.1080/09546634.2020.1717417. Epub 2020 Jan 28.
Randomized controlled trials (RCTs) demonstrated the advantages of an aerosol foam formulation of calcipotriol/betamethasone dipropionate (Cal/BD) in patients with psoriasis. In this review, we investigated whether such benefits could also be obtained in real-world clinical practice.
PubMed was searched for studies reporting real-world data in patients with psoriasis treated with Cal/BD aerosol foam.
Three large real-world studies with Cal/BD aerosol foam were identified: a prospective non-interventional study from Germany, a medical chart review from the US, and a retrospective non-interventional study from Spain. Some key findings included the following: high levels of adherence to treatment (82-93%); after 4 weeks, about 50% of patients achieved complete/almost complete responses; at final assessment, 85-95% of patients were extremely satisfied/very satisfied/satisfied with Cal/BD aerosol foam; all healthcare providers were satisfied or somewhat satisfied with the efficacy of Cal/BD foam and they reported similar findings for symptom improvements (itch, pain, erythema/redness, flaking, and plaque thickness). Global ratings by investigators/healthcare providers for symptom control, overall efficacy and the emotional status of patients were also very high (75-100%).
The results from real-world studies undertaken in diverse healthcare systems reinforce the positive findings reported in RCTs with Cal/BD aerosol foam in patients with psoriasis.
随机对照试验（RCT）证明了卡泊三醇/倍他米松二丙酸酯（Cal/BD）气雾剂泡沫制剂对银屑病患者的优势。在本综述中，我们调查了在实际临床实践中是否也能获得这些益处。
在PubMed上检索报告使用Cal/BD气雾剂泡沫治疗银屑病患者的真实世界数据的研究。
确定了三项关于Cal/BD气雾剂泡沫的大型真实世界研究：一项来自德国的前瞻性非干预性研究、一项来自美国的病历回顾研究以及一项来自西班牙的回顾性非干预性研究。一些关键发现包括：治疗依从性高（82%-93%）；4周后，约50%的患者获得完全/几乎完全缓解；在最终评估时，85%-95%的患者对Cal/BD气雾剂泡沫极其满意/非常满意/满意；所有医疗服务提供者对Cal/BD泡沫的疗效满意或 somewhat 满意，他们报告了症状改善（瘙痒、疼痛、红斑/发红、脱屑和斑块厚度）的类似结果。研究者/医疗服务提供者对症状控制、总体疗效和患者情绪状态的总体评分也非常高（75%-100%）。
在不同医疗系统中进行的真实世界研究结果强化了RCT中关于Cal/BD气雾剂泡沫对银屑病患者的积极发现。
